HIV disease progression in Australia in the time of combination antiretroviral therapies

被引:46
作者
Correll, PK [1 ]
Law, MG [1 ]
McDonald, AM [1 ]
Cooper, DA [1 ]
Kaldor, JM [1 ]
机构
[1] Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW 2010, Australia
关键词
D O I
10.5694/j.1326-5377.1998.tb123370.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine the effect of recent developments in antiretroviral therapy on HIV disease progression and survival. Design: Retrospective cohort study. Participants and setting: -Two cohorts of people with HIV were defined retrospectively from the records of a large immunology laboratory. The first cohort were subjects whose CD4+ T cell counts had dropped to 200 x 10(6)/L during 1990, and the second were subjects whose CD4+ T cell counts had dropped to 200 x 10(6)/L in 1994. Main outcome measures: HIV disease progression and survival was determined over a minimum three years of follow-up for each cohort (ie, 1990-1993; 1994-1997). Results: 346 subjects were included in the analysis (193 subjects from 1990 and 153 from 1994). The relative risk of progression to AIDS in the 1994 cohort compared with the 1990 cohort was 0.57 (95% confidence interval, 0.35-0.91; P=0.018) and the relative risk of death was 0.20 (95% confidence interval, 0.08-0.49; P<0.001). Conclusions: There were 43% fewer AIDS cases and 80% fewer deaths in the time following the increased availability of combination antiretroviral therapy in Australia.
引用
收藏
页码:469 / 472
页数:4
相关论文
共 14 条
[1]  
Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
[2]  
Centers for Disease Control, 1992, MMWR-MORBID MORTAL W, V41, pRR
[3]  
Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3
[4]   Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study [J].
Egger, M ;
Hirschel, B ;
Francioli, P ;
Sudre, P ;
Wirz, M ;
Flepp, M ;
Rickenbach, M ;
Malinverni, R ;
Vernazza, P ;
Battegay, M ;
Bernasconi, E ;
Burgisser, P ;
Erb, P ;
Fierz, W ;
Grob, P ;
Gruninger, U ;
Jeannerod, L ;
Ledergerber, B ;
Luthy, R ;
Matter, L ;
Opravil, M ;
Paccaud, F ;
Perrin, L ;
Pichler, W ;
Piffaretti, GC ;
Rutschmann, O ;
Zanetti, G .
BMJ-BRITISH MEDICAL JOURNAL, 1997, 315 (7117) :1194-1199
[5]   A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less [J].
Hammer, SM ;
Squires, KE ;
Hughes, MD ;
Grimes, JM ;
Demeter, LM ;
Currier, JS ;
Eron, JJ ;
Feinberg, JE ;
Balfour, HH ;
Dayton, LR ;
Chodakewitz, JA ;
Fischl, MA .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) :725-733
[6]   A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter [J].
Hammer, SM ;
Katzenstein, DA ;
Hughes, MD ;
Gundacker, H ;
Schooley, RT ;
Haubrich, RH ;
Henry, WK ;
Lederman, MM ;
Phair, JP ;
Niu, M ;
Hirsch, MS ;
Merigan, TC ;
Blaschke, TF ;
Simpson, D ;
McLaren, C ;
Rooney, J ;
Salgo, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (15) :1081-1090
[7]  
*HIV AIDS CLIN TRI, 1997, ANT THER HIV INF PRI
[8]  
HOOVER DR, 1995, AIDS, V9, P145, DOI 10.1097/00002030-199509020-00005
[9]  
Ioannidis JPA, 1996, AM J EPIDEMIOL, V144, P1074, DOI 10.1093/oxfordjournals.aje.a008881
[10]  
*NAT CTR HIV EP CL, 1996, HIV AIDS REL DIS AUS